NVAX - Company ID 0001000694
NOVAVAX INC trades as NVAX and has a market capitalization of $1.54 B, making it the #2341 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.12B, up 64.7% from the prior year and net income of $440.30M. This page tracks NOVAVAX INC through 1,627 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years NOVAVAX INC's revenue grew from $15.35M to $1.12B, a compound annual growth rate of 61.1%. Net profit margin expanded from -1823.5% to 39.2% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13D/A | - | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-07 |
| Major company event | 8-K | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-06 |
| SCHEDULE 13G | - | 2026-04-30 |
| Insider trade | 4 | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-27 |
| Proxy statement | DEF 14A | 2026-04-27 |
The largest companies sharing NOVAVAX INC's SEC industry classification (biological products, (no diagnostic substances)).
NOVAVAX INC (NVAX) has a market capitalization of $1.54 B as of 2026-07-09, ranking #2341 among US-listed companies.
NOVAVAX INC reported revenue of $1.12B for fiscal year 2025, an increase of 64.7% year over year.
Yes. NOVAVAX INC reported net income of $440.30M in its latest fiscal year.